340B trade associations and covered entities submitted public comments overwhelmingly supporting the Biden administration’s proposal to rescind a Trump-era rule requiring community health centers to pass along savings on insulin and injectable epinephrine to low-income patients.
Drug manufacturer Eli Lilly, one of the nation’s three insulin manufacturers, opposed rescinding the regulation and its underlying presidential executive order.
340B trade associations and covered entities submitted public comments overwhelmingly supporting the Biden administration’s proposal to rescind a Trump-era rule requiring community health centers to pass along savings on insulin and injectable epinephrine to low-income patients. Drug manufacturer Eli Lilly, one of the nation’s three insulin manufacturers, opposed rescinding the regulation and its underlying presidential executive order.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.